CY1117879T1 - Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων - Google Patents

Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων

Info

Publication number
CY1117879T1
CY1117879T1 CY20161100786T CY161100786T CY1117879T1 CY 1117879 T1 CY1117879 T1 CY 1117879T1 CY 20161100786 T CY20161100786 T CY 20161100786T CY 161100786 T CY161100786 T CY 161100786T CY 1117879 T1 CY1117879 T1 CY 1117879T1
Authority
CY
Cyprus
Prior art keywords
water
salt
crystalline
acetone
carbon atoms
Prior art date
Application number
CY20161100786T
Other languages
English (en)
Inventor
Claudio Giordano
Erwin Waldvogel
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of CY1117879T1 publication Critical patent/CY1117879T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • C07C231/24Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αφορά μια νέα διεργασία για την παραγωγή ή/και καθαρισμό του άλατος της ένωσης (S)-2-[4-(2-φθοροβενζυλοξυ) βενζυλαμινο]προπαναμίδη, δηλ. ραλφιναμίδη, ή του αντίστοιχου R-εναντιομερούς, με μεθανοσουλφονικό οξύ σε υψηλές αποδόσεις και πολύ υψηλή εναντιομερική και χημική καθαρότητα στη μορφή του κρυσταλλικού άνυδρου πολύμορφου το οποίο ταυτοποιείται ως μορφή Α, όπου το εν λόγω άλας είναι κατ' ουσία απαλλαγμένο από προσμίξεις που έχουν γονοτοξική επίδραση, όπως (C1-C5)αλκανυλμεθανοσουλφονικά, και υπολειπόμενους διαλύτες γνωστούς ως πιθανούς προδρόμους αυτών, όπως (C1-C5)αλκανόλες ή εστέρες αυτών με κατώτερα αλκανοϊκά οξέα. Η διεργασία προβλέπει (i) παραγωγή ή/και κρυστάλλωση του άλατος, από νερό, ακετόνη, μια αλειφατική κετόνη 4-5 ατόμων άνθρακα ή μίγματα αυτών με νερό, ή (ii) πολτοποίηση του στερεού άλατος με (α) νερό, (β) ένα μίγμα νερού με ακετόνη ή μια αλειφατική κετόνη 4-5 ατόμων άνθρακα, (γ) ακετόνη, μια αλειφατική κετόνη 4-5 ατόμων άνθρακα ή ένα μίγμα αυτής, ή (iii) έκθεση του στερεού άλατος σε ρεύμα αέρα που έχει υψηλό βαθμό σχετικής υγρασίας, και, όταν το λαμβανόμενο προϊόν αποτελείται συνολικά ή εν μέρει από κρυστάλλους μορφής Η κρυσταλλικού ημιένυδρου ψευδοπολύμορφου, μετατροπή του εν λόγω προϊόντος σε κρυστάλλους άνυδρης μορφής Α μέσω υποβολής αυτού σε αφαίρεση νερού. Η μορφή Η κρυσταλλικού ημιένυδρου ψευδοπολύμορφου της μεθανοσουλφονικής ραλφιναμίδης, ή το R-εναντιομερές αυτής, είναι ένα χρήσιμο ενδιάμεσο για τη λήψη του κρυσταλλικού άνυδρου πολύμορφου Α απαλλαγμένου από τις παραπάνω προσμίξεις που έχουν γονοτοξική επίδραση ή/και υπολειπόμενους διαλύτες γνωστούς ως προδρόμους αυτών, και επιδεικνύει ένα φυσικοχημικό προφίλ που συνεισφέρει σημαντικά πλεονεκτήματα στον σχεδιασμό και ανάπτυξη στερεών μορφών δοσολογίας, συγκεκριμένα, φαρμακοτεχνικών μορφών τροποποιημένης αποδέσμευσης.
CY20161100786T 2010-04-27 2016-08-10 Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων CY1117879T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
EP11714958.3A EP2563355B1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers

Publications (1)

Publication Number Publication Date
CY1117879T1 true CY1117879T1 (el) 2017-05-17

Family

ID=42634917

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100786T CY1117879T1 (el) 2010-04-27 2016-08-10 Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων

Country Status (28)

Country Link
US (2) US9505708B2 (el)
EP (1) EP2563355B1 (el)
JP (3) JP5808392B2 (el)
KR (1) KR101851118B1 (el)
CN (2) CN102858330B (el)
AR (1) AR085171A1 (el)
AU (1) AU2011246707B2 (el)
BR (1) BR112012027623B1 (el)
CA (1) CA2794389C (el)
CY (1) CY1117879T1 (el)
DK (1) DK2563355T3 (el)
EA (1) EA021389B1 (el)
ES (1) ES2590128T3 (el)
HK (2) HK1179881A1 (el)
HR (1) HRP20161077T1 (el)
HU (1) HUE030504T2 (el)
IL (1) IL222532A (el)
LT (1) LT2563355T (el)
ME (1) ME02509B (el)
MX (1) MX342697B (el)
NZ (2) NZ700221A (el)
PL (1) PL2563355T3 (el)
PT (1) PT2563355T (el)
RS (1) RS55084B1 (el)
SI (1) SI2563355T1 (el)
SM (1) SMT201600266B (el)
TW (1) TWI492919B (el)
WO (1) WO2011134763A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858330B (zh) * 2010-04-27 2015-07-22 纽朗制药有限公司 用于制备拉非酰胺甲磺酸盐或其r-对映异构体的方法
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
JP4350508B2 (ja) 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ, インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
KR101233711B1 (ko) 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
NZ553970A (en) * 2004-09-10 2010-01-29 Newron Pharm Spa Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PL2474521T3 (pl) * 2006-06-19 2017-01-31 Newron Pharmaceuticals S.P.A. 2-[4-(3- i 2-fluorobenzyloksy)benzyIoamino]propanoamidy o wysokim stopniu czystości do zastosowania jako leki i preparaty farmaceutyczne je zawierające
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
KR101709498B1 (ko) * 2007-12-11 2017-02-23 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 2­[4­(3­ 또는 2­플루오로벤질옥시)벤질아미노]프로판아미드의 제조방법
CA2707646C (en) 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
CN102858330B (zh) * 2010-04-27 2015-07-22 纽朗制药有限公司 用于制备拉非酰胺甲磺酸盐或其r-对映异构体的方法

Also Published As

Publication number Publication date
AU2011246707B2 (en) 2014-11-20
HUE030504T2 (en) 2017-05-29
EP2563355A1 (en) 2013-03-06
EA201291116A1 (ru) 2013-04-30
LT2563355T (lt) 2016-09-26
IL222532A (en) 2017-09-28
EA021389B1 (ru) 2015-06-30
DK2563355T3 (en) 2016-09-12
KR101851118B1 (ko) 2018-04-23
JP2017197553A (ja) 2017-11-02
JP5808392B2 (ja) 2015-11-10
CN105037188B (zh) 2017-06-23
MX2012012093A (es) 2012-12-17
CN102858330A (zh) 2013-01-02
AR085171A1 (es) 2013-09-18
JP2015180664A (ja) 2015-10-15
SI2563355T1 (sl) 2016-10-28
HRP20161077T1 (hr) 2016-10-21
SMT201600266B (it) 2016-08-31
US9505708B2 (en) 2016-11-29
CN102858330B (zh) 2015-07-22
NZ700221A (en) 2016-04-29
WO2011134763A1 (en) 2011-11-03
PL2563355T3 (pl) 2016-12-30
CA2794389C (en) 2016-08-23
JP2013528577A (ja) 2013-07-11
CA2794389A1 (en) 2011-11-03
US9856207B2 (en) 2018-01-02
JP6345154B2 (ja) 2018-06-20
PT2563355T (pt) 2016-09-02
NZ602648A (en) 2014-10-31
HK1213872A1 (zh) 2016-07-15
JP6450420B2 (ja) 2019-01-09
KR20130094212A (ko) 2013-08-23
TW201139344A (en) 2011-11-16
ME02509B (me) 2017-02-20
BR112012027623A2 (pt) 2016-08-09
EP2563355B1 (en) 2016-06-08
HK1179881A1 (en) 2013-10-11
US20130039983A1 (en) 2013-02-14
BR112012027623B1 (pt) 2021-07-06
US20170029365A1 (en) 2017-02-02
IL222532A0 (en) 2012-12-31
ES2590128T3 (es) 2016-11-18
MX342697B (es) 2016-10-10
TWI492919B (zh) 2015-07-21
CN105037188A (zh) 2015-11-11
RS55084B1 (sr) 2016-12-30

Similar Documents

Publication Publication Date Title
CY1117879T1 (el) Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
AR080819A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
MEP34408A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
BRPI0915692B8 (pt) compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
MA32297B1 (fr) Procede de preparation de derives d'acide 1-(2-halobiphenyl-4-yl)-cyclopropane carboxylique
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
BR112014014060A2 (pt) processo para a preparação de travoprosta
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112017017066A2 (pt) método de preparação para praziquantel e compostos intermediários do mesmo
EA201201666A1 (ru) Промежуточные соединения агомелатина и способ их получения
FR2926080B1 (fr) Procede de synthese de derives d'acide hydroxy-bisphosphonique
ES2540211T3 (es) Proceso para preparar una amida de un ácido carboxílico pirazólico
ITMI20120311A1 (it) Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
JP2004511477A (ja) R(+)α−リポ酸の合成
CA2858126A1 (en) Synthesis of calebin-a and its biologically active analogs
PT1673365E (pt) Processo para a preparação de z-flupentixol
ES2381813T3 (es) Procedimiento para la preparación de ésteres del ácido 2,3,4,9-tetrahidro-1H-beta-carbolin-3-carboxílico
EA202190170A1 (ru) Способ получения ингибитора бромодомена
BR112014029361A2 (pt) método de produção de ácido tereftálico e seus derivados
WO2012070896A3 (en) Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid
ES2383715T3 (es) Proceso para producir ácido 2-pipecólico-2',6'-xilidida útil como un producto intermedio para la preparación de anestésicos locales
RU2013135374A (ru) Способ получения кальциевых солей оптически активной [d] или рацемической [d, l] гомопантотеновой кислот
JP2017066077A (ja) イミダゾール−2−カルボン酸エステル誘導体又はその塩の製造方法